|
||||
Case for Discussion You are an editor for the Journal of Novel Diagnostics. Your recently handled a manuscript that compared two new diagnostic tests for detection of a genetic defect. Test 1 is marketed by Genetix, Inc. and test 2 is marketed by Probes Unlimited. The manuscript concludes that test 1 is superior in terms of reliability and accuracy. Following peer review and minor revision, you accept the paper and it appears in print. Shortly after publication, you receive a letter from the Vice President for Research at Probes Unlimited. She claims that examination of the methods section of the paper reveals that the authors used test 2 in a manner that significantly deviates from the instructions provided by Probes Unlimited. Moreover, she claims that the senior author on the paper has previously received research grants from Genetix, Inc. Is this "sloppy science" or scientific fraud. What course of action do you take? used with permission |
||||